[1] [1] Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer—clinical challenges and opportunities[J]. Nat Rev Clin Oncol, 2020, 17(9): 527-540.

[2] [2] Luo G, Jin K, Deng S, et al. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(2): 188409.

[5] [5] Sunami Y, Huler J, Zourelidis A, et al. Cancer-associated fibroblasts and tumor cells in pancreatic cancer microenvironment and metastasis: Paracrine regulators, reciprocation and exosomes[J]. Cancers (Basel), 2022, 14(3): 744.

[6] [6] Sunami Y, Bker V, Kleeff J. Targeting and reprograming cancer-associated fibroblasts and the tumor microenvironment in pancreatic cancer[J]. Cancers (Basel), 2021, 13(4): 697.

[7] [7] Chang YT, Peng HY, Hu CM, et al. Pancreatic cancer-derived small extracellular vesical ezrin activates fibroblasts to exacerbate cancer metastasis through STAT3 and YAP-1 signaling pathways[J]. Mol Oncol, 2023, 17(8): 1628-1647.

[9] [9] Song Y, Wang L, Wang K, et al. COL12A1 acts as a novel prognosis biomarker and activates cancer-associated fibroblasts in pancreatic cancer through bioinformatics and experimental validation[J]. Cancers (Basel), 2023, 15(5): 1480.

[11] [11] Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer[J]. Lancet, 2020, 395(10242): 2008-2020.

[12] [12] Huang J, Lok V, Ngai CH, et al. Worldwide burden of, risk factors for, and trends in pancreatic cancer[J]. Gastroenterology, 2021, 160(3): 744-754.

[13] [13] Malik S, Westcott JM, Brekken RA, et al. CXCL12 in pancreatic cancer: its function and potential as a therapeutic drug target[J]. Cancers (Basel), 2021, 14(1): 86.

[14] [14] Leask A. A centralized communication network: Recent insights into the role of the cancer associated fibroblast in the development of drug resistance in tumors[J]. Semin Cell Dev Biol, 2020, 101: 111-114.

[15] [15] Domen A, Quatannens D, Zanivan S, et al. Cancer-associated fibroblasts as a common orchestrator of therapy resistance in lung and pancreatic cancer[J]. Cancers (Basel), 2021, 13(5): 987.

[16] [16] Czekay RP, Cheon DJ, Samarakoon R, et al. Cancer-associated fibroblasts: mechanisms of tumor progression and novel therapeutic targets[J]. Cancers (Basel), 2022, 14(5): 1231.

[17] [17] Malvia S, Chintamani C, Sarin R, et al. Aberrant expression of COL14A1, CELRS3, and CTHRC1 in breast cancer сells[J]. Exp Oncol, 2023, 45(1): 28-43.

[18] [18] Wu Y, Xu Y. Integrated bioinformatics analysis of expression and gene regulation network of COL12A1 in colorectal cancer[J]. Cancer Med, 2020, 9(13): 4743-4755.

[19] [19] Jiang X, Wu M, Xu X, et al. COL12A1, a novel potential prognostic factor and therapeutic target in gastric cancer[J]. Mol Med Rep, 2019, 20(4): 3103-3112.

[20] [20] Yao W, Yao Y, He W, et al. PABPC1 promotes cell proliferation and metastasis in pancreatic adenocarcinoma by regulating COL12A1 expression[J]. Immun Inflamm Dis, 2023, 11(7): e919.

[21] [21] Li Y, Su Z, Wei B, et al. Bioinformatics analysis identified MMP14 and COL12A1 as immune-related biomarkers associated with pancreatic adenocarcinoma prognosis[J]. Math Biosci Eng, 2021, 18(5): 5921-5942.